HRP20110253T1 - Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze - Google Patents

Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze Download PDF

Info

Publication number
HRP20110253T1
HRP20110253T1 HR20110253T HRP20110253T HRP20110253T1 HR P20110253 T1 HRP20110253 T1 HR P20110253T1 HR 20110253 T HR20110253 T HR 20110253T HR P20110253 T HRP20110253 T HR P20110253T HR P20110253 T1 HRP20110253 T1 HR P20110253T1
Authority
HR
Croatia
Prior art keywords
inhibitors
antagonists
agonists
compound according
compound
Prior art date
Application number
HR20110253T
Other languages
English (en)
Croatian (hr)
Inventor
Manuel Vieira Ara�jo Soares Da Silva Patr�cio
Alexander Learmonth David
Beliaev Alexander
Original Assignee
Bial-Portela & Ca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110253(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial-Portela & Ca filed Critical Bial-Portela & Ca
Publication of HRP20110253T1 publication Critical patent/HRP20110253T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20110253T 2007-05-08 2008-05-06 Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze HRP20110253T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds
PCT/PT2008/000019 WO2008136695A1 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase

Publications (1)

Publication Number Publication Date
HRP20110253T1 true HRP20110253T1 (hr) 2011-05-31

Family

ID=38198874

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110253T HRP20110253T1 (hr) 2007-05-08 2008-05-06 Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze

Country Status (29)

Country Link
US (5) US8481582B2 (enExample)
EP (1) EP2155731B1 (enExample)
JP (1) JP5559677B2 (enExample)
KR (1) KR101598482B1 (enExample)
CN (1) CN101687858B (enExample)
AR (2) AR066457A1 (enExample)
AT (1) ATE499367T1 (enExample)
AU (1) AU2008246443B2 (enExample)
BR (1) BRPI0811275B8 (enExample)
CA (1) CA2686387C (enExample)
CL (1) CL2008001321A1 (enExample)
CY (1) CY1111517T1 (enExample)
DE (1) DE602008005141D1 (enExample)
DK (1) DK2155731T3 (enExample)
ES (1) ES2360841T3 (enExample)
GB (1) GB0708818D0 (enExample)
HR (1) HRP20110253T1 (enExample)
IL (1) IL201921A (enExample)
MX (1) MX2009012041A (enExample)
NO (1) NO20093275L (enExample)
NZ (1) NZ580962A (enExample)
PL (1) PL2155731T3 (enExample)
RS (1) RS51692B (enExample)
RU (1) RU2501796C2 (enExample)
SI (1) SI2155731T1 (enExample)
TW (1) TWI458722B (enExample)
UA (1) UA104844C2 (enExample)
WO (1) WO2008136695A1 (enExample)
ZA (1) ZA200908612B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
US9212130B2 (en) * 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
BR112013015864B1 (pt) 2010-12-22 2021-11-09 Bial - Portela & C.A., S.A. Processo para purificar um composto de forma cristalina a de (r)-5-(2-benzilamino)etil)-1- (6,8-difluorocroman-3-il)-1h-imidazol-2(3h)-tiona
JP5981539B2 (ja) * 2011-06-29 2016-08-31 バイアル−ポルテラ アンド シーエー，エス．エー． プロセス
RU2718055C2 (ru) * 2012-11-14 2020-03-30 Биал - Портела и Кa, С.А. Производные 1,3-дигидроимидазол-2-тиона для применения в лечении легочной артериальной гипертензии и повреждения легкого
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
UY37879A (es) 2017-09-13 2019-03-29 Amgen Inc Compuestos de bisamida que activan el sarcómero y sus usos
JP7167155B2 (ja) 2017-12-04 2022-11-08 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ ドーパミン－β－ヒドロキシラーゼ阻害剤
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
WO2020102053A1 (en) * 2018-11-12 2020-05-22 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
AU2022213938A1 (en) * 2021-01-26 2023-09-07 Asieris Pharmaceuticals (Shanghai) Co., Ltd. Pathway modulator, pharmaceutical composition having same, use thereof, and therapeutic method using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
ES2201104T3 (es) 1994-04-26 2004-03-16 Roche Palo Alto Llc Derivados de benzociclohexilimidazoltiona.
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
GB2393958A (en) * 2002-10-11 2004-04-14 Portela & Ca Sa Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
US7125904B2 (en) 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Also Published As

Publication number Publication date
WO2008136695A1 (en) 2008-11-13
CA2686387A1 (en) 2008-11-13
JP5559677B2 (ja) 2014-07-23
CN101687858B (zh) 2012-12-26
RU2501796C2 (ru) 2013-12-20
HK1142898A1 (en) 2010-12-17
AU2008246443A8 (en) 2010-01-07
BRPI0811275B1 (pt) 2020-01-07
MX2009012041A (es) 2010-02-18
BRPI0811275A2 (pt) 2014-12-23
IL201921A (en) 2013-11-28
CN101687858A (zh) 2010-03-31
US20100137390A1 (en) 2010-06-03
US20210261533A1 (en) 2021-08-26
CA2686387C (en) 2015-06-30
ATE499367T1 (de) 2011-03-15
US20130345275A1 (en) 2013-12-26
KR20100017546A (ko) 2010-02-16
EP2155731A1 (en) 2010-02-24
CL2008001321A1 (es) 2008-12-26
RU2009145270A (ru) 2011-06-20
US20170369478A1 (en) 2017-12-28
CY1111517T1 (el) 2015-08-05
US8481582B2 (en) 2013-07-09
US20190322648A1 (en) 2019-10-24
RS51692B (sr) 2011-10-31
DE602008005141D1 (de) 2011-04-07
AU2008246443A1 (en) 2008-11-13
AR066457A1 (es) 2009-08-19
ES2360841T3 (es) 2011-06-09
IL201921A0 (en) 2010-06-16
DK2155731T3 (da) 2011-05-02
UA104844C2 (uk) 2014-03-25
TWI458722B (zh) 2014-11-01
JP2010526136A (ja) 2010-07-29
AU2008246443B2 (en) 2013-07-11
PL2155731T3 (pl) 2011-07-29
ZA200908612B (en) 2010-11-24
SI2155731T1 (sl) 2011-05-31
EP2155731B1 (en) 2011-02-23
NO20093275L (no) 2010-02-04
GB0708818D0 (en) 2007-06-13
AR112789A2 (es) 2019-12-11
KR101598482B1 (ko) 2016-02-29
BRPI0811275B8 (pt) 2021-05-25
US9630951B2 (en) 2017-04-25
TW200918525A (en) 2009-05-01
NZ580962A (en) 2012-05-25

Similar Documents

Publication Publication Date Title
JP2010526136A5 (enExample)
RU2009145270A (ru) Производные 1, 3-дигидроимидазол-2-тиона в качестве ингибиторов дофамин-бета-гидроксилазы
Froestl Chemistry and pharmacology of GABAB receptor ligands
JP7252972B2 (ja) ３－ヒドロキシ－Ｎ－（３－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）フェニル）ピロリジン－１－カルボキサミド誘導体
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
RU2009132881A (ru) Производные пуринила и их применение в качестве модуляторов калиевых каналов
PE20050462A1 (es) COMPUESTOS DE 5,7-DIAMINOPIRAZOLO[4,3-d]PIRIMIDINAS COMO INHIBIDORES DE LA FOSFODIESTERASA TIPO 5 (PDE-5)
EA201170061A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
WO2019193516A2 (en) Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
JP2017530185A (ja) テトラヒドロイソキノリン誘導体
Song et al. Design and synthesis of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors
Bae et al. Unusual deoxygenation and reactivity studies related to O 6-(benzotriazol-1-yl) inosine derivatives
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.
AU2018225312A1 (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor
CN117624073B (zh) 双环苯酚类化合物及其应用
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
Vangveravong et al. Synthesis of N-substituted 9-azabicyclo [3.3. 1] nonan-3α-yl carbamate analogs as σ2 receptor ligands
Clark et al. Discovery and SAR development of 2-(phenylamino) imidazolines as postacyclin receptor antagonists
EP2970201B1 (en) 6-[4-(1h-imidazol-2-yl)piperidin-1-yl]pyrimidin-4-amine derivatives as modulators of kinase activity
Lavrador-Erb et al. The discovery and structure–activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia
JP7502299B2 (ja) 置換キサンチン誘導体
Luo et al. Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor
TW201718475A (zh) 尿素衍生物及其用途
Huang et al. Synthesis of [18F] 4‐amino‐N‐(3‐chloro‐4‐fluorophenyl)‐N′‐hydroxy‐1, 2, 5‐oxadiazole‐3‐carboximidamide (IDO5L): a novel potential PET probe for imaging of IDO1 expression
Wang et al. A new facile synthetic route to [11C] GSK189254, a selective PET radioligand for imaging of CNS histamine H3 receptor